The changes that drive differentiation create a large potential for the emergence of abnormal 24 cells that need to be removed before they contribute to further development or the germline. 25
Abstract
Introduction 37 The appropriate regulation of apoptosis during embryonic development is essential for 38 maintaining the right balance between the elimination of suboptimal cells and the availability 39 of sufficient cell numbers to sustain embryo growth 1 . The maintenance of this balance is most 40 acutely evident in the lead up to gastrulation, when the mouse epiblast not only undergoes the 41 process of germ layer specification, but also displays a significant expansion in cell numbers, 42 from 150 at E5.5 to 15,000 cells at E7.5 2 . This rapid proliferation of cells is concomitant with 43 the substantial cellular changes that accompany gastrulation, most notably extinction of the 44 pluripotency network and activation of differentiation genes in a lineage-specific manner. 45
Any abnormal or mis-specified cell, which cannot perform these changes appropriately, 46 needs to be removed from the embryo to prevent them from contributing to further 47 development or the germline, which is also specified around E6.5 3 . Hence, a wave of cell 48 death takes place in the mouse embryo at E6.5, most likely reflecting the elimination of these 49 abnormal cells 4, 5 . 50
One way by which the embryo facilitates the elimination of aberrant cells is through lowering 51 the apoptotic threshold as it proceeds from a pre-implantation to an early post-implantation 52 stage of development. Indeed, whilst low doses of UV irradiation do not induce apoptosis in 53 mouse pre-implantation embryos, these same low doses lead to a strong apoptotic response in 54 the post-implantation epiblast 6 . Similarly, although cells with a range of genetic defects, 55
including chromosome fragmentation or chromosome mis-segregation survive pre-56 implantation development, they are efficiently eliminated by apoptosis during early post-57 implantation development 7-10 . Subsequently, it has been proposed that the post-implantation 58 epiblast is primed for death, and therefore hyper-responsive to apoptotic signals 6, 11 . 59
The mitochondrial apoptotic pathway is tightly regulated by a balance between pro-and anti-60 apoptotic factors belonging to the BCL-2 family. The binding of the anti-apoptotic proteins 61 (e.g BCL-2, BCL-XL, A1 or MCL-1) to their pro-apoptotic BCL-2 family counterparts (e.g. 62 BIM, BID, PUMA, NOXA or BAD) prevents the induction of apoptosis. When this balance 63 is lost, BIM or BID bind to the apoptotic effector molecules BAX and BAK, which induce 64 mitochondrial outer membrane permeabilization (MOMP) and caspase activation 12 . We have 65 previously shown that, in the post-implantation epiblast, this balance is at least in part 66 maintained by microRNAs (miRNAs) of the miR-20, miR-92, and miR-302 families. These 67 miRNAs target Bim (Bcl2l11) and maintain it in a state that is poised for activation 11 . 68
However, it is worth noting that mutation of Bim does not prevent the endogenous wave of 69 cell death occurring during early mouse development, suggesting that other factors must be 70 contributing to making the epiblast hypersensitive to death signals 11 . 71
The balance between mitochondrial fusion and fission, termed mitochondrial dynamics, has 72 emerged over the last few years as an important regulator of the apoptotic response. 73
Mitochondrial dynamics are facilitated by proteins such as MFN1, MFN2 and OPA1, that 74 promote fusion and DRP1 or MFF, that promote fission [13] [14] [15] . During cell death, remodelling 75 of the cristae network regulated by OPA1 16 and DRP1 17, 18 is required for release of 76 cytochrome C and subsequent apoptosis. DRP1-induced mitochondrial fragmentation is also 77 coupled to the later stages of apoptosis [19] [20] [21] [22] . Finally, MFN1-induced fusion has been shown to 78 promote a mitochondrial size that is permissive for BAX function 23 . Therefore, the regulators 79 of mitochondrial dynamics play a variety of different roles in the apoptotic process. In the 80 developing embryo, mitochondrial shape undergoes substantial changes around the time of 81 implantation 24 . During pre-implantation stages mitochondria are round and have a low cristae 82 density 25 , but later in development mitochondria elongate and cristae density increases 24 . 83 These observations raise the possibility that changes in mitochondrial dynamics may play 84 roles in regulating the changes in apoptotic threshold that occur during early development. 85
Here we have identified that a change in mitochondrial dynamics increases the sensitivity to 86 cell death signals in cells of the post-implantation epiblast. For this, we combined 87 experiments in the embryo, with studies using embryonic stem cells (ESCs), which capture 88 the naïve pluripotent state found in the pre-implantation epiblast, and in epiblast stem cells 89 (EpiSCs), which resemble the primed pluripotent post-implantation epiblast 26 . We find that 90 although primed pluripotent cells show high mitochondrial apoptotic priming, their increased 91 sensitivity to cell death is not due to differential expression of members of the BCL-2 pro-92
and anti-apoptotic family. In contrast, we observed that decreased mitochondrial fission 93
correlates with the readiness of cells to undergo apoptosis. Furthermore, we demonstrate that 94 manipulating DRP1 activity is sufficient to change the apoptotic threshold of pluripotent 95 cells. Together, these results demonstrate that changes in mitochondrial dynamics influence 96 the apoptotic priming status of cells and contribute to the elimination of aberrant cells during 97 early embryonic development. 98
Results

99
Pluripotent cells become hypersensitive to cell death upon exit of naïve pluripotency. 100 We set out firstly to characterise the apoptotic sensitivity of the different pluripotent cell 101 types found during early mouse development. Previous studies have shown that whilst cells 102 from the pre-implantation embryo are relatively resistant to low doses of UV radiation, the 103 early post-implantation cells respond to the same low doses of UV by undergoing apoptosis 6 . 104
In line with these findings, we observed no overt apoptosis in E3.5 mouse embryos treated 105 with the DNA damage-inducing drug etoposide for 1.5h, but we detected a strong apoptotic 106 response when the etoposide treatment was applied to E6.5 embryos (Supplementary Figure  107 1A-B). 108
We next tested whether the observed differential sensitivity to apoptosis is also apparent in 109
ESCs and EpiSCs, the two in vitro counterparts of the pre-and post-implantation epiblast 26 . 110
We have previously shown that loss of miRNAs leads to an upregulation of BIM expression 111 and a consequent induction of apoptosis in EpiSCs 11 . To test if miRNAs also regulate 112 apoptosis in ESCs, we induced Dicer deletion in Dicer Fx/Fx ESCs by tamoxifen 113 administration, as we had previously done for EpiSCs 11 . This led to miRNA depletion 114 (Supplementary Figure 1C) and an up-regulation of BIM expression similar to that found in 115
EpiSCs ( Figure 1A ). However, in contrast to what was seen in EpiSCs, the increase in BIM 116 expression did not cause apoptosis in ESCs This suggests that mouse ESCs are more resistant to apoptosis than EpiSCs. 118 Importantly, we found that the differential apoptotic response of ESCs and EpiSCs was also 119 evident upon exposing these cells to different sources of stress. Induction of oxidative stress 120 with 1µM sodium arsenite for 16 hours produced a 3-fold increase in Annexin V positive 121
ESCs, but a 7-fold increase in Annexin V positive EpiSCs ( Figure 1D ). Similarly, induction 122 of endoplasmic reticulum (ER) stress with increasing doses of thapsigargin for 16 hours led 123 to a small change in the basal levels of cleaved Caspase 3 in ESCs, whereas the same 124 treatment induced a robust apoptotic response in EpiSCs ( Figure 1E ). Overall, these results 125
indicate that EpiSCs exhibit an increased sensitivity to apoptosis when compared to ESCs, 126 thus recapitulating the features observed in their in vivo counterparts. 127
The mitochondrial apoptotic pathway is primed for cell death in primed pluripotent 128 stem cells. 129 We next addressed if the differences in apoptotic response between naïve and primed 130 pluripotent cells were reflected at the level of the mitochondrial apoptotic pathway. This 131 pathway is regulated by the relative expression of pro-apoptotic and anti-apoptotic BCL-2 132 family members 12 . This balance can be artificially changed, for example by inhibiting BCL-133 2/XL activity with BH3 mimetics such as ABT-737. We observed that 24h treatment of 134
EpiSCs with ABT-737 led to a strong increase in the percentage of cells displaying (1) 135 MOMP (Supplementary Figure 1E ), (2) Annexin V positivity ( Figure 2A) and (3) cleaved 136 caspase-3 expression ( Figure 2B ). In contrast, treatment with ABT-737 failed to induce 137 apoptosis in ESCs, even at the highest concentration used ( Figure 2A -B and Supplementary 138 Figure 1E -F). These findings are strengthened by the observation that ABT-737 leads to 139 cytochrome C release from the mitochondria in EpiSCs, but not ESCs ( Figure 2B ). To test 140 the physiological significance of these observations, we treated pre-and post-implantation 141 mouse embryos with 2μM ABT-737 for 1.5h. Similar to what we observed in vitro, we found 142 that this treatment induced apoptosis in epiblast cells of E6.5 embryos, but not in inner cell 143 mass cells of E3.5 embryos ( Figure 2C and Supplementary Figure 1F ). 144
Next, we determined whether the enhanced sensitivity of EpiSCs to BCL2/BCLXL inhibition 145 was dependent on BIM. For this we transfected previously tested siRNAs targeting Bim 11 146 into EpiSCs and treated them with ABT-737. We observed that this was sufficient to suppress 147 the apoptotic response induced by BCL2/BCL-XL inhibition ( Figure 2D ), further 148
highlighting the importance of BIM for the apoptotic response of EpiSCs. Given that the 149 differences in apoptotic response between ESCs and EpiSCs appear to be mediated by the 150 mitochondrial apoptotic pathway, we measured the level of mitochondrial apoptotic priming 151 of these cells by analysing the kinetics of mitochondrial membrane depolarization induced by 152 BIM and BID BH3 peptides 27 . We observed that the depolarization of the mitochondrial 153 membrane potential was significantly more pronounced in EpiSCs than in ESCs for both 154 these peptides ( Figure 2E ). Together these results indicate that primed pluripotent cells have 155 a lower apoptotic threshold than naïve cells due to enhanced sensitivity of the mitochondrial 156 pathway. 157
The relative expression of pro-and anti-apoptotic BCL2 family members does not 158 explain the different apoptotic threshold of ESCs and EpiSCs. 159
To address if differences in the relative expression of pro-and anti-apoptotic BCL2 family 160 members underpin the different apoptotic response of ESCs and EpiSCs, we compared the 161 expression of these proteins in each cell type. We observed no significant difference in the 162 expression of the pro-apoptotic activator proteins PUMA, BIM, BID or BAD in either whole 163 cell or mitochondrial extracts between these two cell types ( Figure 3A) . Similarly, we did not 164 observe any difference in the expression of the pro-apoptotic effector proteins BAX or BAK 165 ( Figure 3B ). In contrast, when anti-apoptotic proteins were analysed, we found little 166 difference in the expression of BCL-XL, MCL1 or A1, but significantly higher expression of 167 BCL-2 in EpiSCs, in both whole cell and mitochondrial extracts ( Figure 3C ). Whilst a higher 168 expression of anti-apoptotic protein expression may seem counterintuitive given the 169 enhanced sensitivity to death of EpiSCs, this elevated BCL-2 expression is likely part of the 170 adaptation of these cells to their low apoptotic threshold 28 . 171
To determine if the balance of expression of pro-and anti-apoptotic factors changes 172 differently in ESCs and EpiSCs upon induction of apoptosis, we analysed the expression of 173 key BCL-2 family members after treating these cells with 5µM ABT-737 for 24 hours. In 174 these experiments we analysed the expression of the anti-apoptotic BCL-2 family members 175 as well as BIM expression, as BIM is required for the apoptotic response to ABT-737 ( Figure  176 2D). However, we observed no significant change in the levels of expression of BCL-2, 177 BCL-XL, A1, MCL-1 or BIM between ABT-737 treated samples and controls in either whole 178 cell or mitochondrial extracts of ESCs or EpiSCs ( Supplementary Figure 2A-B ). This 179
suggests that the induction of apoptosis does not significantly shift the balance of pro-and 180
anti-apoptotic BCL-2 family expression. Together, these results indicate that the relative 181 expression of BCL-2 family proteins is not the cause of the higher sensitivity to apoptosis of 182 primed pluripotent cells. 183
High levels of mitochondrial fission are observed in naïve pluripotent cells when 184
compared to primed cells. 185 Mitochondrial dynamics have been suggested as a mechanism that contributes to the 186 regulation of the mitochondrial apoptotic threshold 13 . The mitochondria of ESCs and pre-187 implantation embryos have been shown to be rounded 25 and to elongate upon 188 differentiation 29, 30 . Analysis of mitochondrial morphology in ESCs revealed rounded 189 doughnut shaped mitochondria in agreement with previous studies 30 . In contrast, the 190 mitochondria of EpiSCs were more elongated ( Figure 4A ). Importantly, these differences 191
were also seen in vivo, with E3.5 inner cell mass cells and E4.5 epiblast cells having rounded 192 mitochondria and the mitochondria of E6.5 epiblast cells being elongated and forming 193 networks ( Figure 4B ). 194
The differences in mitochondrial shape between naïve and primed pluripotent cells suggest 195 that these cell types have different mitochondrial dynamics. We therefore studied the 196 expression of fusion and fission regulators in ESCs and EpiSCs. While we observed no 197 difference in the expression of the fusion regulators MFN1, MFN2 or OPA1 between these 198 cell types, we noticed that ESCs had significantly higher levels of total DRP1 and p-DRP1 199 (S616), a phosphorylation event that induces fission 31 ( Figure 4C -D). This indicates that 200 naïve pluripotent cells have higher fission activity. To determine if the higher p-DRP1 201 expression is responsible for the rounded mitochondrial shape of ESCs, we knocked-out 202
Drp1 by CRISPR-Cas9. Although Drp1 -/-ESCs remained pluripotent, their mitochondria 203 became elongated and hyperfused ( Figure 5A -B and Supplementary Figure 3A) . These 204 results indicate that DRP1-induced mitochondrial fission is required for the fragmented 205 mitochondrial shape observed in ESCs. 206 DRP1 plays a key role in determining the apoptotic threshold of naïve and primed 207 pluripotent cells. 208
To evaluate whether DRP1 levels determine the apoptotic threshold of pluripotent cells we 209 first analysed the effects of loss of Drp1. In the first instance we compared the apoptotic 210 response of wild-type and Drp1 -/-ESCs to ER stress or oxidative stress. We observed that a 211 significantly higher proportion of Drp1 -/cells treated with thapsigargin or sodium arsenite 212
show MOMP ( Figure 5C ). We next analysed the kinetics of MOMP in response to BH3 213 peptides and observed that both BIM and BID BH3 peptides were more efficient at inducing 214 mitochondrial outer membrane depolarization in Drp1 -/-ESCs than wild-type cells ( Figure  215 5E). This indicates that loss of Drp1 is sufficient to lower the apoptotic threshold of ESCs 216 ( Figure 2E ). Importantly, this change in sensitivity to cell death induction was unlikely to be 217 a secondary consequence of a disruption of the metabolism of mutant cells, as Drp1 -/-ESCs 218 did not show decreased glycolysis or oxidative phosphorylation rates when compared to 219 wild-type cells. Instead, mutant cells displayed an increased spare respiratory capacity, an 220 increased response to pyruvate and an increased glycolytic rate (Supplementary Figure 3B -221 E), suggesting that mitochondrial fission enhances the bioenergetic rate of pluripotent cells. 222 DRP1 has been shown to be involved in the remodelling of the mitochondrial cristae and the 223 subsequent release of cytochrome C into the cytoplasm 17, 18 , an event downstream of MOMP. 224 We therefore analysed if cytochrome C release is compromised in Drp1 -/-ESCs. We 225 observed that Drp1 -/-ESCs displayed lower levels of cytoplasmic cytochrome C upon 226 thapsigargin treatment (Supplementary Figure 3F ). This suggests that DRP1 is likely to play 227 at least two roles in the apoptotic response in pluripotent cells. First, it impedes the pro-228 apoptotic roles of BCL-2 family members and second it promotes cytochrome C release by 229
helping the remodelling of the mitochondrial cristae. 230
Given the roles of DRP1 in determining the apoptotic response of ESCs, we next wanted to 231 analyse its importance during ESCs differentiation. During differentiation p-DRP1 levels 232 decrease ( Figure 4C ) and therefore we analysed the effects of Drp1 overexpression (Drp1 OE ) 233 in differentiating ESCs. We have previously shown that culturing ESCs for 3 days in N2B27 234 leads to a post-implantation epiblast-like state 32 . We therefore cultured Drp1 OE cells for 3 235 days in N2B27 and found that this led to sustained DRP1 expression and increase in p-DRP1 236 levels (Supplementary Figure 4A -C and Supplementary Figure 5A -D). Importantly, this 237 increase in p-DRP1 did not prevent exit of naïve pluripotency but induced mitochondria to 238 adopt a more rounded morphology ( Figure 6A -C and Supplementary Figure 5A-B ). We 239 therefore tested the effect on the apoptotic response of a sustained increase in p-DRP1 during 240 the onset of ESC differentiation. We found that after 3 days in differentiation conditions, 241
Drp1 OE cells displayed not only lower basal cleaved caspase 3 levels ( Figure 6D and 242
Supplementary Figure 5A -C), but also significantly reduced levels of cleaved Caspase 3 in 243 response to treatment with thapsigargin, sodium arsenite or ABT-737 ( Figure 6E -G and 244
Supplementary Figure 5A ,C-D). Together with our findings in Drp1 -/-ESCs, these results 245
suggest that the decrease in DRP1 and p-DRP1 levels observed during exit of pluripotency 246 play an important role in sensitising cells to apoptosis. 247
Discussion
248
The removal of aberrant cells during development is important to prevent them from 249 contributing to further development and the germline. To facilitate this elimination cells 250 become hypersensitive to apoptosis during the onset of differentiation 6, 11, 33, 34 . Here we 251
show that DRP1 regulates apoptotic priming in these cells via influencing mitochondrial 252 dynamics. We show that upon exit of naïve pluripotency mitochondria form complex 253 networks due to a decrease in mitochondrial fission induced by a loss of DRP1 254
phosphorylation. We also demonstrate that this loss of DRP1 activity changes the apoptotic 255 threshold, as deletion of Drp1 facilitates the early stages of apoptosis and its over-expression 256 protects against apoptosis. Together, these findings highlight the pivotal role that DRP1 plays 257 in modulating the response to cell death during differentiation. 258
When considering how DRP1 levels might affect the apoptotic response, a number of 259 possibilities arise. In the first instance, it has been shown that mitochondrial shape affects the 260 ability of BAX to permeabilise the outer mitochondria membrane. It was found that 261 mitochondrial fusion establishes a mitochondrial size that is permissive to the function of 262 pro-apoptotic BCL2 family members and that mitochondrial hyper-fragmentation inhibited 263 the ability of BAX to associate with and permeabilise the outer mitochondria membrane 23 . In 264 line with this possibility, the rounded and fragmented shape of the mitochondria of naive 265 pluripotent cells due to the high levels of fission induced by DRP1 would help explain the 266 high apoptotic threshold of these cells. 267
An alternative, but not mutually exclusive, possibility that could explain how DRP1 affects 268 the apoptotic response, is by modulating the entry of calcium into the mitochondria. It is well 269 known that the degree of contact between the endoplasmic reticulum (ER) and mitochondria 270 has profound implications for the function of each of these organelles 13, 35 . For example entry 271 of calcium into the mitochondria is thought to be regulated by ER-mitochondria contacts. 272
Moreover, ER-mitochondria contact sites are thought to be a site of reactive oxygen species 273 (ROS) signalling, which also affects calcium signals delivery to the mitochondria 36 . We 274 observe that both mutation of DRP1 or its overexpression changes the apoptotic response to 275 thapsigargin, a drug that increases calcium levels in the cytoplasm, and to sodium arsenite, 276
which induces oxidative stress. Therefore, our results raise the possibility that by regulating 277 mitochondrial shape, DRP1 levels control the degree of contact between the ER and 278 mitochondria, with the formation of elongated mitochondrial networks induced by decreased 279 fission during differentiation favouring increased mitochondria ER-contacts and in this way 280 facilitating calcium entry into the mitochondria. 281
It is worth highlighting that the involvement of DRP1 in the early apoptotic events involving 282 permeabilization of the mitochondrial membrane are separable from the downstream release 283 of cytochrome C, which others have shown and we also find is promoted by DRP1 17, 18, 37 . In 284 principle, this would represent two opposing roles for DRP1: slowing mitochondrial 285 membrane permeabilization, but facilitating cytochrome C release. One way to reconcile 286 these potentially opposing roles is that either each one requires different levels of DRP1, with 287 the release cytochrome C being possible with just baseline DRP1 levels. Acknowledgements 319 We would like to Massimo Signore and Juan Pedro Martinez Barbera for critical discussion. 320
We thank Stephen Rothery for guidance and advice with confocal microscopy. Gratitude also 321 goes to James Elliot for performing cell sorting. ESCs and EpiSCs 11, 46 were cultured in the presence of 0.3 487 mM 4-OH-Tamoxifen for three days and left untreated from the third day onwards as 488 previously described 11 . 489
For BCL2/BCL-XL inhibition ABT-737 (Selleckchem) was added to the media for 24 h at 490 the stated concentration. Oxidative stress and ER stress were induced by adding sodium 491 arsenite (Sigma Aldrich) or Thapsigargin (Sigma Aldrich) for 16 h at the stated 492 concentrations. To induce Bim knockdown, a previously tested Bim siRNA (Mm_Bcl2l11_2 493
FlexiTube siRNA, Qiagen) 11 was transfected into EpiSCs at a final concentration of 75nM 494
using HiPerFect transfection reagent (Qiagen) according to manufacturers' instructions. 495
Transfection of Flexi-Tube Negative Control siRNA (Qiagen) at a final concentration of 496 75nM was used as negative control. 497
Flow cytometry analysis: Annexin V staining and MMP measurement 498
For apoptosis detection by flow cytometry, Annexin V-APC (Thermo Fisher Scientific) was 499 used in combination with Propidium Iodide (Sigma) according to manufacturer's instructions. 500
Briefly, approximately 2x10 5 cells were stained in 100µl of Annexin V Binding Buffer (0.1% 501 BSA in 10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH7.4) containing APC conjugated 502
Annexin V for 15 minutes in the dark, after which 0.1 mg/ml propidium iodide was added 503 and the samples immediately analysed by flow cytometry. Loss of mitochondrial membrane 504 potential was measured using the fluorescent dyes DiOC6 or TMRM. Briefly, 2x10 5 cells 505
were re-suspended in PBS containing 40 nM DiOC6 (Sigma) or 100nM TMRM (T668, 506 ThermoFisher Scientific), incubated for 15 min at 37°C and analyzed by flow cytometry. 507
Data was acquired with a BD LSRII cytometer and analyzed with the FlowJo software (BD). 508
Stem cells immunofluorescence 509
For immunostaining ESCs and EpiSCs were fixed for 10min in 4%PFA at room temperature, 510 permeabilised in 0,4% Triton-X100/PBS for 5 minutes at room temperature, blocked in 511 10%BSA/ 0,1% Triton X-100/PBS and incubated overnight at 4°C in primary antibody 512 diluted in 1%BSA/0,1%Triton X-100 (anti-Cleaved Caspase 3 Asp175, Cell Signalling, 513 1/100; anti-Nanog (14-5761 80 eBioscience, 1/100, anti ATP-b (Ab14730, Abcam -1:200). 514
Alexa-Fluor conjugated secondary antibodies (Thermo Fisher Scientific) were used at 1/500 515 dilution in 1%BSA/0,1%Triton X-100. Cells were mounted for visualization in Vectashield 516
with DAPI (Vector Laboratories). Images were acquired with a Zeiss confocal microscope 517
and analysed with the Fiji software 47 . 518
Mitochondrial Staining 519
Cells were washed with PBS and fixed with 3.7% formaldehyde diluted in serum free media 520
for 15 min at 37°C, 5% CO 2 . Cell were washed two times with PBS and incubated with pre-521 cooled acetone for 5 min at -20°C. Cells were washed two times with PBS and incubated 522
with blocking/permeabilization (5% BSA, 0.4% Triton-X in PBS) solution for 30 min at RT 523 before incubating with the primary antibody O/N at 4°C. Excess antibody was removed and 524 cells washed three times in PBS, then incubated with the secondary antibody for 45 min at 525
RT. Before mounting with Vectashield with DAPI, secondary antibody was removed and cell 526
washed again three times in PBS. 527
Images were acquired in a LSM Z800 Confocal microscope and processed with FIJI. Images 528 for deconvolution were acquired with the same microscope and further processed with the 529 software Huygens. Deconvolution analysis was performed with the support and advice from 530
Mr. Stephen Rothery from the Facility for Imaging by Light Microscopy (FILM) at Imperial 531 College London. 532 Primary antibodies used for immunofluorescence: Tom20 (1/100, Santa Cruz), 533 Abcam), Nanog (1:100, eBioscience), Gata4 (1:100, Santa Cruz), Sox2 (1:100, R&D). Alexa-534
Fluor conjugated secondary antibodies (Invitrogen) were used at a concentration of 1:600. 535
Mitochondria circularity measurements were done with a plugin from FIJI that calculates 536 object circularity according to the formula circularity=4π(area/perimeter 2 ). A circularity 537 value of 1.0 indicates a perfect circle. As the value approaches 0.0, it indicates an 538 increasingly elongated polygon. The calculations were done on ATP-b immunostained 539
images. 540
Western blot analysis 541
Western blot was performed according to established protocols described elsewhere 11 . 542
Briefly, protein samples were collected in Laemmli buffer and denatured for 10 minutes at 543 95 o C. All samples were run in polyacrylamide gels and transferred to nitrocellulose 544 membranes. Blocking was performed in 5% milk in TBST buffer and primary antibody 545 incubation was done overnight at 4 o C in TBST containing 5% BSA. The following antibodies 546
were used at the stated concentration: anti-Bim/Bod (Enzo, 1/1000), anti-Puma (Abcam,  547 1/1000), anti-Bid (Cell Signaling, 1/1000), anti-Bad (Santa Cruz Biotechnology, 1/500), 548
anti-Bax N20 (Santa Cruz Biotechnology, 1/1000), anti-Bcl2 (BioLegend, 1/500), anti-Bcl-549 XL (Santa Cruz Biotechnology, 1/1000), anti-MCL1 (Rockland, 1/10000), anti-Bcl2A1 550 (R&D Systems, 1/500), anti-Hexokinase II (Cell Signaling, 1/1000), anti-ATP-b (Abcam, 551 1/1000), anti-c C (BD Pharmigen, 1/1000), anti-Erk1/2 (Sigma, 1/20000), anti-Cleaved 552
Caspase 3 Asp175 (Cell Signaling, 1/1000), anti-alpha Tubulin (Cell Signaling, 1/2000), anti-553 beta Actin (Santa Cruz Biotechnology, 1/1000), anti-Bak (Millipore, 1/1000) anti-Oct3/4 554 (Santa Cruz Biotechnology, 1/1000), anti-Nanog (eBiosciences, 1/1000), anti-Tom20 (Santa 555
Cruz Biotechnologies, 1/1000), anti-Drp1 (Cell Signalling, 1/1000) anti-pDRP1 (S616) (Cell 556
Signaling 1/1000), anti-Mfn1 (Abcam, 1/1000), anti-Mfn2 (Abcam, 1/1000), anti-Opa1 (BD, 557 1/1000). Western blot quantification was performed using the Fiji software 47 . 558
Mitochondria purification and cytochrome C release assay 559
For mitochondria purification cells were trypsinized and washed twice in 10 packed cell 560 volumes of 1mM TrisHCl pH 7.4, 0.13M NaCl, 5mM KCl, 7.5 mM MgCl 2 followed by 561 centrifugation at 370g for 10 minutes. After the second wash pelleted cells were re-suspended 562 in 6 packed cell volumes of homogenization buffer (10mM TrisHCl pH6.7, 10mM KCl, 0.15 563 mM MgCl 2 , 1mM PMSF, 1mM DTT) and incubated for 10 minutes on ice. Cells were 564 homogenized in a glass homogenizer until achieving approximately 60% cell breakage. 565
Homogenate was poured into a tube containing 1 packed cell volume of 2M sucrose solution, 566 mixed and centrifuged at 1200g for 5 minutes to pellet unbroken cells, nuclei and debris. This 567 treatment was repeated twice discarding the pellet, followed by 10 minutes centrifugation at 568 7000g in order to pellet the mitochondria. Mitochondrial pellet was re-suspended in 3 packed 569 cell volumes of mitochondrial suspension buffer (10mM TrisHCl pH6.7, 0.15mM MgCl 2 , 570 0.25% sucrose, 1mM PMSF, 1mM DTT) and centrifuged for 5 minutes at 9500g. Final 571 mitochondrial pellet was re-suspended in 1x Laemmli Buffer and boiled at 95ºC for 10 572 minutes for western blot analysis. 573
For the separation of cytosolic and membrane fractions in order to investigate cytochrome C 574 release, cells were washed twice with ice cold PBS and incubated for 10 minutes rocking on 575 ice in Digitonin Buffer (20mM HEPES/KOH pH7.5, 100mM sucrose, 2.5mM MgCl 2 , 576 100mM KCL, 1mM DTT, 0.0025% digitonin) supplemented with Complete protease 577 inhibitors (Roche). The supernatant was collected as cytosolic fraction and Triton X-100 578
Extraction Buffer 48 was added to the plates followed by 30 minute incubation rocking on ice. 579
The resulting supernatant was taken as membrane fraction. 580
Embryo culture, treatment and immunofluorescence 581 E3.5 embryos were obtained by flushing of the uterus at 3.5 days post coitum and cultured in 582 M16 media containing DMSO, 1µM Etoposide (Sigma) or 2µM ABT-737 (Selleckchem). 583 E6.5 embryos were dissected from pregnant females at 6.5 days post coitum and cultured in 584 N2B27 media (see Epiblast Stem Cell culture conditions) containing DMSO, 585 1µM Etoposide or 2µM For immunostaining, embryos were fixed in 4% PFA/0.1%Tween/0.01% Triton X-587 100/PBS (10 min for 3.5dpc and 4.5dpc, 20min for 6.5dpc) at room temperature, 588 permeabilized in 0.5% Triton X-100/PBS for 15min (3.5dpc and 4.5dpc) Corrected cell fluorescence was measured using (Fiji, Image J) as previously described 599 (reference below). An outline was drawn around each embryo. Area, mean fluorescence and 600 integrated density were measured. In addition, adjacent areas were also selected an measured 601 as background readings. Corrected cellular fluorescence (CCF) was calculated using the 602 formula: CCF = integrated density -(area of selected cell × mean fluorescence of 603 background readings. Cleaved Caspase 3 signal was normalised to DAPI 49 . 604
BH3 profiling 605
The assay was performed following the protocol described by Anthony Letai's laboratory 27 . 606
Briefly, 15μL of 2x peptides diluted in DTEB buffer (135mM threalose, 10mM HEPES KOH 607 pH 7.5, 50mM KCl, 20μM EGTA, 20μM EDTA, 0.10% BSA, 5mM succinic acid) were 608 added to each well of a dark 384 well plate (Nunc). Cells were dissociated with trypsin, 609
counted and resuspended at 2.67x10 6 cells/mL. Equal volume of cells and dying mix (4x 610 digitonin (0.01%), 4x JC-1 (4mM) and Oligomycin (40μg/mL)) were incubated for 10 611 minutes at room temperature protected from light. 15μL of this mix was added per well of the 612 384 well plate. DMSO and CCCP (Sigma) were used as no-depolarization and full 613 depolarization controls. BID, BIM, BMF and a peptide control were tested in this profile. 614
Each sample was loaded by triplicate and at least three biological replicates were analysed. 615
Fluorescence was measured every 5 minutes for a period of 70 minutes, with a 544/590 filter 616 in a FluoStar Omega plate reader (BMG Omega). Percentage of depolarization was 617 calculated by normalizing the data to the membrane potential of cells that have not been 618 exposed to peptides but have been treated with DMSO (vehicle) The metabolic function of cells was assessed by extracellular flux analysis using Seahorse 659 XF24 (Agilent Technologies, UK). On the day prior to the assay, 5x10 4 cells per well were 660 seeded on 0.1% gelatin-coated (Sigma, UK) 24-well plates and grown in 300 µL of 661 pluripotency maintenance conditions. Cells were washed, just before the assay, with the assay 662 media and left with a final volume of the 600 µL per well. The plate was then equilibrated on 663 a non-CO 2 incubator at 37ºC for 30 min. The assay media consisted in unbuffered DMEM 664 (D5030 -Sigma, UK), reconstituted with 1.83 g.L -1 of NaCl in dH 2 O, that was supplemented 665 on the day of the assay according to the test performed. For the OCR measurements the assay 666 media was supplemented with 0.5 g.L -1 of glucose (Sigma, UK) and 2 mM of L-glutamine 667 (Life Technologies, UK), while for the ECAR measurements the media was supplemented 668 with 1 mM of Sodium Pyruvate and 2 mM of L-glutamine (both from Life Technologies, 669 UK), pH 7.4 at 37ºC. 670 Assays were performed with 5 biological replicates of each cell type and 4 wells were left 671 without cells for background correction measurements. Both ECAR and OCR measurements 672 were performed on the same plate. The assay parameters for both tests were calculated 673 following the Seahorse assay report generator (Agilent Technologies, UK). 674
The protocol for the assay consisted of 4 baseline measurements and 3 measurements after 675 each compound addition. Compounds (all from Sigma, UK) used in OCR and ECAR tests 676 were prepared in the supplemented assay media. For the OCR, test the following compounds 677 were added: 2.5 µM oligomycin (OM), 300 nM Carbonyl cyanide-4-(trifluoromethoxy) 678 phenylhydrazone (FCCP) and a mixture of rotenone and antimycin A at 6 µM each (R&A). 679
For the ECAR test, the following compounds were added: 2.5 mM and 10 mM of glucose, 680 2.5 µM of oligomycin (OM), and a 50 mM of 2-deoxyglucose (2-DG). 681
At the end of the assay, cells were fixed and stained with Hoechst. Both OCR and ECAR 682 were normalised to cell number, determined by manual cell counts using FIJI software. 683
Statistical methods 684
Statistical analysis was performed using GraphPad Prism software. Statistical methods used 685 are indicated in the relevant figure legends. No randomization or blinding was used in 686 experiments. Sample sizes were selected based on the observed effects and listed in the figure  687 legends . 
